Breaking News Instant updates and real-time market news.

NKTR

Nektar

$15.50

-0.21 (-1.34%)

07:33
03/20/17
03/20
07:33
03/20/17
07:33

Nektar: NKTR-181 meets primary, secondary endpoints in Phase 3 SUMMIT-07 study

Nektar Therapeutics announced positive results from the SUMMIT-07 Phase 3 efficacy study of NKTR-181, a first-in-class opioid analgesic. NKTR-181 is a new chemical entity that is the first full mu-opioid agonist molecule designed to provide potent pain relief without the high levels of euphoria that can lead to abuse and addiction with standard opioids.1 The U.S. FDA has granted the investigational medicine NKTR-181 Fast Track designation for the treatment of moderate to severe chronic pain. "The data from this efficacy study are extremely important because they demonstrate that NKTR-181 produces strong analgesia in patients suffering from chronic pain while NKTR-181 has also demonstrated significantly lower abuse potential than oxycodone in a human abuse potential study," said clinical investigator Martin Hale, M.D., medical director of Gold Coast Research. "While standard opioid analgesics, including abuse-deterrent formulations, have been the most effective way to treat chronic pain, they are associated with serious safety concerns and many opioid-naive patients fear taking them because of the potential for abuse and addiction. The data for NKTR-181 suggest that it is a transformational pain medicine that could fundamentally change how we treat patients with chronic pain conditions." The SUMMIT-07 study compared twice-daily dosing of NKTR-181 tablets to placebo in the treatment of over 600 patients with moderate to severe chronic low back pain who were new to opioid therapy (opioid-naive). The clinical trial met the primary efficacy endpoint of the study in demonstrating significantly improved chronic back pain relief with NKTR-181 compared to placebo (p=0.0019). Key secondary endpoints of the study were also met with high statistical significance. The study also demonstrated that NKTR-181 had a favorable safety profile and was well tolerated. During the double-blind randomized treatment period, the most commonly reported adverse events for patients (greater than5%) were nausea (10.4%) and constipation (8.7%) in the NKTR-181 arm as compared to nausea (6.0%) and constipation (3.0%) in the placebo arm.

  • 29

    Mar

  • 01

    Apr

NKTR Nektar
$15.50

-0.21 (-1.34%)

12/21/16
PIPR
12/21/16
NO CHANGE
PIPR
Piper lays out top BioPharma picks for 2017
Piper Jaffray analysts laid out their top BioPharma picks for 2017. Analyst Richard Purkiss favors Pfizer (PFE) and Eli Lilly (LLY) as his top large pharma picks. Analyst Joshua Schimmer calls Gilead (GILD) and Alexion (ALXN) his top large cap picks. Analyst David Amsellem names Horizon Pharma (HZNP) his top specialty pharma pick. Piper's other top Biopharma picks for 2017 include ACADIA (ACAD), Aimmune (AIMT), Akorn (AKRX), Alnylam (ALNY), Axovant Sciences (AXON), Cara Therapeutics (CARA), CoLucid Pharmaceuticals (CLCD), Eale Pharmaceuticals (EGRX), Exelixis (EXEL), Ionis Pharmaceuticals (IONS), Mallinckrodt (MNK), Neurocrine (NBIX), Nektar (NKTR), Otonomy (OTIC), Reata Pharmaceuticals (RETA), Rigel Pharmaceuticals (RIGL), Ignyta (RXDX), Theravance Biopharma (TBPH), Versartis (VSAR) and Voyager Therapeutics (VYGR). The analysts look for recent momentum in BioPharma to continue in 2017. They believe innovation and potentially repatriation should lead to increased merger activity.
01/03/17
JANY
01/03/17
NO CHANGE
JANY
Janney sees pricing, rising rates as biotech headwinds in 2017
Janney Capital analyst Debjit Chattopadhyay noted that, on a relative basis vs. the Nasdaq, 2016 was the worst year for the Nasdaq biotechnology index (NBI) since 1994 and he believes the "outlook for 2017 isn't particularly rosy" given structural challenges for the sector along with rising interest rates. He cautions about overenthusiasm on M&A, as Chattopadhyay thinks "cash rich pharma may choose to return cash to shareholders through increased buybacks and dividends," and he believes "M&A, if any, is likely to lead to short-term relief rallies and may not represent a broader turn in sentiment." Meanwhile, broader discussion on healthcare spending and regulatory changes are likely to be bigger drivers of biotech sentiment during 2017 than M&A, said Chattopadhyay, who listed bluebird bio (BLUE), Galapagos NV (GLPG), Vertex (VRTX), Clovis (CLVS) and Nektar (NKTR) as on the firm's 2017 biotechnology focus list.
01/06/17
BTIG
01/06/17
INITIATION
Target $22
BTIG
Buy
Nektar initiated with a Buy at BTIG
BTIG analyst Robert Hazlett started Nektar Therapeutics with a Buy rating and $22 price target. Several "intriguing" emerging therapeutics along with multiple near-term catalysts make the shares attractive, Hazlett tells investors in a research note.
01/26/17
PIPR
01/26/17
NO CHANGE
PIPR
Overweight
Celgene acquisition highlights underappreciated Nektar asset, says Piper Jaffray
After Celgene (CELG) announced this morning a deal to acquire Delinia for $300M plus up to $475M in potential milestones, Piper Jaffray analyst Joshua Schimmer noted that the company's lead asset, DEL106, being developed for autoimmune disorders, is similar to Nektar's (NKTR) NKTR-358. While many investors are familiar with Nektar's immune-oncology program, NKTR-214, far fewer are familiar with NKTR-358, though both represent potential blockbuster opportunities if successful, Schimmer tells investors. He keeps an Overweight rating on Nektar, which he identifies as one of his top mid-cap picks.

TODAY'S FREE FLY STORIES

CXP

Columbia Property

$21.68

-0.27 (-1.23%)

20:50
03/27/17
03/27
20:50
03/27/17
20:50
Upgrade
Columbia Property rating change  »

Columbia Property…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Apr

SPG

Simon Property

$166.15

-1.8 (-1.07%)

20:45
03/27/17
03/27
20:45
03/27/17
20:45
Conference/Events
Simon Property management to meet with Canaccord »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Mar

  • 27

    Apr

HALO

Halozyme

$14.27

0.74 (5.47%)

20:41
03/27/17
03/27
20:41
03/27/17
20:41
Conference/Events
Halozyme management to meet with Canaccord »

Meeting to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Mar

  • 01

    Apr

  • 06

    Jun

AYR

Aircastle

$23.44

0.03 (0.13%)

20:38
03/27/17
03/27
20:38
03/27/17
20:38
Conference/Events
Aircastle management to meet with Canaccord »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

  • 29

    Mar

NEE

NextEra Energy

$131.10

-1.7 (-1.28%)

20:30
03/27/17
03/27
20:30
03/27/17
20:30
Conference/Events
NextEra Energy management to meet with Guggenheim »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

  • 30

    Mar

M

Macy's

$27.93

-0.24 (-0.85%)

20:26
03/27/17
03/27
20:26
03/27/17
20:26
Conference/Events
Macy's management to meet with Guggenheim »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

PPBI

Pacific Premier

$36.35

-0.05 (-0.14%)

, HEOP

Heritage Oaks

$12.62

0.02 (0.16%)

20:25
03/27/17
03/27
20:25
03/27/17
20:25
Conference/Events
Heritage Oaks to host special shareholder meeting »

Special Shareholder…

PPBI

Pacific Premier

$36.35

-0.05 (-0.14%)

HEOP

Heritage Oaks

$12.62

0.02 (0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 27

    Mar

  • 15

    May

CCL

Carnival

$58.87

0.27 (0.46%)

, MKC

McCormick

$101.36

0.35 (0.35%)

20:25
03/27/17
03/27
20:25
03/27/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

CCL

Carnival

$58.87

0.27 (0.46%)

MKC

McCormick

$101.36

0.35 (0.35%)

DRI

Darden

$75.58

-1.13 (-1.47%)

FDS

FactSet

$174.55

-2.18 (-1.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

  • 28

    Mar

  • 28

    Mar

  • 29

    Mar

  • 04

    Apr

  • 03

    May

SYY

Sysco

$52.04

-0.77 (-1.46%)

20:17
03/27/17
03/27
20:17
03/27/17
20:17
Conference/Events
Sysco management to meet with Guggenheim »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

  • 29

    Mar

  • 20

    Jun

MNK

Mallinckrodt

$44.33

1.24 (2.88%)

20:13
03/27/17
03/27
20:13
03/27/17
20:13
Conference/Events
Mallinckrodt management to meet with Guggenheim »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 28

    Mar

  • 29

    Mar

  • 08

    May

OGE

OGE Energy

$35.41

-0.28 (-0.78%)

20:10
03/27/17
03/27
20:10
03/27/17
20:10
Conference/Events
OGE Energy management to meet with Guggenheim »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 28

    Mar

CMCSA

Comcast

$37.11

-0.27 (-0.72%)

, CMCSK

Comcast

20:03
03/27/17
03/27
20:03
03/27/17
20:03
Periodicals
Comcast to expand streaming video service, Reuters says »

Comcast plans to rebrand…

CMCSA

Comcast

$37.11

-0.27 (-0.72%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAR

Marriott

$93.17

-0.33 (-0.35%)

20:02
03/27/17
03/27
20:02
03/27/17
20:02
Conference/Events
Marriott management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Mar

FBR

Fibria Celulose

$8.67

-0.22 (-2.47%)

19:58
03/27/17
03/27
19:58
03/27/17
19:58
Conference/Events
Fibria Celulose management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Mar

DXC

DXC Technology

, HPE

HP Enterprise

$22.72

-0.05 (-0.22%)

19:51
03/27/17
03/27
19:51
03/27/17
19:51
Initiation
DXC Technology, HP Enterprise, CSC initiated at Goldman »

DXC Technology initiated…

DXC

DXC Technology

HPE

HP Enterprise

$22.72

-0.05 (-0.22%)

CSC

CSC

$68.05

0.35 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 29

    Mar

  • 29

    Mar

  • 06

    Apr

  • 11

    Apr

  • 12

    Apr

  • 13

    Apr

  • 02

    May

  • 12

    Jun

TRI

Thomson Reuters

$43.56

-0.19 (-0.43%)

19:51
03/27/17
03/27
19:51
03/27/17
19:51
Conference/Events
Thomson Reuters management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Mar

  • 28

    Apr

FIS

FIS

$80.41

0.29 (0.36%)

19:48
03/27/17
03/27
19:48
03/27/17
19:48
Downgrade
FIS rating change at Goldman »

FIS downgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COUP

Coupa Software

$24.00

0.12 (0.50%)

19:48
03/27/17
03/27
19:48
03/27/17
19:48
Conference/Events
Coupa Software management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Mar

  • 06

    Apr

ALK

Alaska Air

$95.00

0.3 (0.32%)

19:44
03/27/17
03/27
19:44
03/27/17
19:44
Conference/Events
Alaska Air management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

  • 30

    Mar

  • 04

    May

TIVO

TiVo

19:40
03/27/17
03/27
19:40
03/27/17
19:40
Conference/Events
TiVo management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

  • 10

    May

TSN

Tyson Foods

$61.84

-0.73 (-1.17%)

, SAFM

Sanderson Farms

$102.76

2.41 (2.40%)

19:40
03/27/17
03/27
19:40
03/27/17
19:40
Hot Stocks
Georgia finds 'low pathogenic' bird flu in commercial flock »

The Georgia Department of…

TSN

Tyson Foods

$61.84

-0.73 (-1.17%)

SAFM

Sanderson Farms

$102.76

2.41 (2.40%)

PPC

Pilgrim's Pride

$22.31

0.05 (0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 20

    Jun

KR

Kroger

$28.93

-0.17 (-0.58%)

19:37
03/27/17
03/27
19:37
03/27/17
19:37
Conference/Events
Kroger management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

  • 30

    Mar

VALE

Vale

$9.34

0.04 (0.43%)

19:30
03/27/17
03/27
19:30
03/27/17
19:30
Hot Stocks
Vale says Fabio Schvartsman appointed as CEO »

Vale announced that,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSM

Nationstar

$15.05

0.1 (0.67%)

19:21
03/27/17
03/27
19:21
03/27/17
19:21
Initiation
Nationstar initiated at Wedbush »

Nationstar initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LNVGY

Lenovo

$12.57

-0.03 (-0.24%)

19:14
03/27/17
03/27
19:14
03/27/17
19:14
Periodicals
Lenovo, Fujitsu postpone PC tie-up, Nikkei says »

Lenovo and Fujitsu will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.